Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients - Seite 2

The primary endpoint was the mean change in average number of monthly migraine days from baseline to Week 12 after the first dose of the study drug. Secondary efficacy endpoints included the proportion of patients achieving ≥50% reduction in major depressive disorder from baseline to Week 12.

The UNITE presentations at AHS will include:

• P-231 Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: results from the UNITE study
  Presentation type: Poster (de novo)
  Session: Friday Midday Exhibits and Posters
  Date/Time: June 16, 2023, 12:35-1:50 PM CT

• IO-05 Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: results of the UNITE study
  Presentation type: Oral
  Session: Industry-Submitted Abstracts
  Date/Time: June 17, 2023, 8:10-8:20 AM CT

• P-232 Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: results of the UNITE study
  Presentation type: Poster (de novo)
  Session: Saturday Midday Exhibits and Posters
  Date/Time: June 17, 2023, 12:45-2:00 PM CT

HEOR Analyses

Results from two analyses will be presented: an economic modeling analysis which estimated potential cost savings associated with use of AJOVY earlier in the treatment cycle; and a real-world database (administrative claims) analysis which examined health care resource use (HCRU) during individual AJOVY treatment cycles to determine if there was an indication of a wearing-off effect with AJOVY.

The two HEOR presentations at AHS will include:

• P-107 Initiation of fremanezumab earlier in the treatment cycle may result in cost savings to payors in the United States
  Presentation type: Poster (encore)
  Session: Friday Midday Exhibits and Posters
  Date/Time: June 16, 2023, 12:35-1:50 PM CT

• P-130 No 'wearing-off effect' seen with fremanezumab in the real‑world: a retrospective, claims-based analysis of migraine-related healthcare resource and acute medication use
  Presentation type: Poster (encore)
  Session: Saturday Midday Exhibits and Posters
  Date/Time: June 17, 2023, 12:45-2:00 PM CT

FINESSE
The FINESSE study is a 49-month (25-month recruitment and 24-month follow-up) multicenter, two-country (Germany/Austria) prospective observational study to evaluate the real-world effectiveness of AJOVY in patients with chronic and episodic migraine during routine clinical practice.